Form 4: Edwards Lifesciences Executive Exercises Options and Sells Shares Under 10b5-1 Plan

Donald E. Bobo Jr., a CVP at Edwards Lifesciences, exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Summary

• On June 12, 2024, Donald E. Bobo Jr., CVP of Strategy/Corporate Development at Edwards Lifesciences Corp, exercised employee stock options to acquire 5,000 shares of common stock at a price of $45.2767 per share.
• Simultaneously, Bobo sold 5,000 shares of common stock at a weighted average price of $87.5393 per share, with individual trades ranging from $87.05 to $88.02.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on December 14, 2023.
• Following these transactions, Bobo directly owns 46,935.7184 shares of common stock and indirectly owns 38,615.0363 shares through a 401(k) and 135,152 shares through a trust.
• Bobo also continues to hold options for 60,500 shares.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing detailing stock transactions by an executive. It doesn't inherently convey positive or negative sentiment about the company's performance or future prospects.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies, and the use of 10b5-1 plans allows insiders to sell shares while avoiding accusations of trading on non-public information. These transactions are closely watched by investors for signals about management's confidence in the company's future prospects.

Comparison to Industry Standards

• Executive compensation packages in the medical device industry often include stock options as a significant component.
• The use of 10b5-1 trading plans is a standard practice among executives at publicly traded companies like Medtronic, Abbott, and Boston Scientific to manage their stock holdings in compliance with insider trading regulations.
• The size and frequency of these transactions are typical for executives at Bobo's level.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership, but the effect is likely minimal given the relatively small number of shares involved.
• The transactions do not directly impact employees, customers, suppliers, or creditors.

Key Dates